Venus Remedies Limited — Etoposide Exporter Profile
Indian Pharmaceutical Exporter · #3 for Etoposide · $988.8K export value · DGFT Verified
Venus Remedies Limited is the #3 Indian exporter of Etoposide with $988.8K in export value and 139 verified shipments. Venus Remedies Limited holds a 9.1% market share in Etoposide exports across 20 countries. The company exports 29 pharmaceutical products worth $86.4M across 6 therapeutic categories.
Venus Remedies Limited — Etoposide Export Profile: Buyers & Destinations
Where Does Venus Remedies Limited Export Etoposide?
| Country | Value | Shipments | Share |
|---|---|---|---|
| MOROCCO | $202.2K | 30 | 19.8% |
| PERU | $165.0K | 9 | 16.2% |
| COLOMBIA | $149.9K | 15 | 14.7% |
| THAILAND | $128.6K | 12 | 12.6% |
| INDONESIA | $119.0K | 14 | 11.7% |
| PAKISTAN | $108.1K | 9 | 10.6% |
| MALAYSIA | $54.8K | 7 | 5.4% |
| ZIMBABWE | $23.0K | 12 | 2.3% |
| COSTA RICA | $19.5K | 7 | 1.9% |
| MYANMAR | $14.9K | 6 | 1.5% |
Venus Remedies Limited exports Etoposide to 21 countries. The largest destination is MOROCCO accounting for 19.8% of Venus Remedies Limited's Etoposide shipments, followed by PERU (16.2%) and COLOMBIA (14.7%). These destinations reflect Venus Remedies Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Etoposide from Venus Remedies Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| M/S OQCORP S.A.C. | PERU | $164.0K | 7 |
| P P | MOROCCO | $140.8K | 20 |
| C M C L | THAILAND | $80.6K | 5 |
| PT MEGA LIFESCIENCES INDONESIA | INDONESIA | $58.4K | 7 |
| PT M L | INDONESIA | $50.1K | 5 |
| ALPHARMA S.A.S. | COLOMBIA | $44.9K | 5 |
| A.S.A.S | COLOMBIA | $43.3K | 4 |
| H P P L | PAKISTAN | $40.5K | 4 |
| PHARMAPROM | MOROCCO | $33.3K | 3 |
| M.E.L.S.B | MALAYSIA | $30.4K | 2 |
Venus Remedies Limited supplies Etoposide to 69 buyers globally. The largest buyer is M/S OQCORP S.A.C. (PERU), followed by P P (MOROCCO) and C M C L (THAILAND). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Etoposide Export Value and How Much Does Venus Remedies Limited Contribute?
India exported $9.5M worth of Etoposide through 2,129 shipments from 237 suppliers to 122 countries, serving 598 buyers globally. Venus Remedies Limited contributes $988.8K to this total, accounting for 9.1% of India's Etoposide exports. Venus Remedies Limited ships Etoposide to 21 countries through 69 buyers.
What Is the Average Shipment Value for Venus Remedies Limited's Etoposide Exports?
Venus Remedies Limited's average Etoposide shipment value is $7.1K per consignment, based on 139 shipments totaling $988.8K. The largest destination is MOROCCO (19.8% of Venus Remedies Limited's Etoposide exports).
How Does Venus Remedies Limited Compare to Other Indian Etoposide Exporters?
Venus Remedies Limited ranks #3 among 237 Indian Etoposide exporters with a 9.1% market share. The top 3 exporters are INTAS PHARMACEUTICALS LIMITED ($4.8M), FRESENIUS KABI ONCOLOGY LIMITED ($1.9M), VENUS REMEDIES LIMITED ($988.8K). Venus Remedies Limited processed 139 shipments to 20 destination countries.
What Etoposide Formulations Does Venus Remedies Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| ETOPOSIDE INJECTION USP ( 100MG/5ML) EAC | $216.5K | 19 |
| ETOPOSIDE INJECTABLE SOLUTION 100MG / 5ML (ETOPUL 100MG/5ML) | $41.5K | 2 |
| ETOPOSIDE INJECTION USP (100MG/5ML) SEDOL 100MG/5ML. B.NO.X4EET021D, X4EET041A,X4EET051A, MD.05/24 ED.04/26 | $30.4K | 1 |
| SEDOL 100 MG ETOPOSIDE CONCENTRATE FORSOLUTION FOR INFUSION 100 MG/5 ML | $30.4K | 2 |
| SEDOL 100MG ETOPOSIDE INJECTION 100MG/5ML EACH ML CONTAINS: ETOPOSIDE 20 MG (PRODUCT SPEC.:USP) | $27.4K | 1 |
| ETOPOSIDE INJECTION 100MG/5ML SEDOL 100MG/5ML BATCH NO. X3LET031C, MFG. DT. 12/2023, EXP. DT. 11/2025 | $26.7K | 3 |
| ETOPOSIDE INJECTION USP 100MG/5ML EAC | $24.4K | 6 |
| ETOSIDE 200 MG ETOPOSIDE INJECTION USP 200MG 10ML B NO X3BH042A X3BH052A X3BH062A MD 02 2023 ED 01 2025 | $23.3K | 1 |
| ETOPOSIDE INJECTION USP(100MG/5ML)EACH M | $21.9K | 2 |
| ETOPOSIDE INJECTION USP 100MG/5ML EACH ML CONTAINS: ETOPOSIDE USP....20MG BENZYL ALCOHOL USP....30 MG POLYSORBATE | $19.6K | 3 |
Venus Remedies Limited exports 109 distinct Etoposide formulations including tablets, capsules, syrups, and combination drugs. The top formulation is ETOPOSIDE INJECTION USP ( 100MG/5ML) EAC with 19 shipments worth $216.5K.
How Does Venus Remedies Limited Compare to Nearest Etoposide Exporters?
Exporters ranked immediately above and below #3 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 1 | INTAS PHARMACEUTICALS LIMITED | $4.8M | 580 | 11 | $8.3K |
| 2 | FRESENIUS KABI ONCOLOGY LIMITED | $1.9M | 126 | 20 | $14.9K |
| 3 | VENUS REMEDIES LIMITED ★ | $988.8K | 139 | 20 | $7.1K |
| 4 | MYLAN LABORATORIES LIMITED | $350.0K | 7 | 2 | $50.0K |
| 5 | HETERO LABS LIMITED | $300.0K | 6 | 2 | $50.0K |
Venus Remedies Limited ranks #3 among 237 Indian Etoposide exporters. Average shipment value of $7.1K compared to the market average of $40.3K. The closest competitors by value are INTAS PHARMACEUTICALS LIMITED and FRESENIUS KABI ONCOLOGY LIMITED.
Which Indian Ports Ship Etoposide Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 357 | 16.8% |
| SAHAR AIR CARGO ACC (INBOM4) | 333 | 15.6% |
| DELHI AIR | 258 | 12.1% |
| DELHI AIR CARGO ACC (INDEL4) | 244 | 11.5% |
| AHEMDABAD AIR ACC (INAMD4) | 141 | 6.6% |
| AHEMDABAD AIR | 135 | 6.3% |
| MUNDRA SEA (INMUN1) | 129 | 6.1% |
| Bombay Air | 96 | 4.5% |
What Other Oncology Products Does Venus Remedies Limited Export?
Venus Remedies Limited also exports these oncology products. Each links to the detailed product page.
Geopolitical & Trade Policy Impact on Venus Remedies Limited's Etoposide Exports
The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Venus Remedies. The ongoing Israel-Iran tensions have led to disruptions in Red Sea shipping routes, increasing transit times and costs for exports to Europe and the Americas. Such disruptions necessitate strategic adjustments in logistics and supply chain management to maintain timely deliveries and cost-effectiveness.
Conversely, the U.S.-China trade tensions have opened avenues for Indian pharmaceutical companies to strengthen their presence in the U.S. market. India now supplies 40% of the U.S.'s generic drug needs, reflecting a growing reliance on Indian manufacturers. (ibef.org) Venus Remedies' recent QIDP designation from the U.S. FDA for VRP-034 positions the company favorably to leverage this opportunity, potentially enhancing its market share in the U.S.
In the European Union, compliance with the Falsified Medicines Directive (FMD) remains critical. Venus Remedies' renewal of the EU-GMP certification indicates their proactive approach to meeting stringent EU regulations, thereby ensuring continued access to European markets. (business-standard.com)
Venus Remedies Limited — Regulatory Compliance & Quality Standards
Maintaining compliance with international regulatory standards is paramount for pharmaceutical exporters. Venus Remedies has demonstrated a consistent commitment to quality, as evidenced by multiple GMP certifications. In addition to the EU-GMP renewal, the company secured GMP certification from Moldova's Ministry of Health in January 2025, covering their antibiotic-carbapenem manufacturing facility. (apnnews.com) Furthermore, the renewal of Ukrainian GMP certification in May 2025 for their Baddi facility underscores their adherence to global quality standards. (apnnews.com)
These certifications not only facilitate market access but also enhance the company's reputation as a reliable supplier of high-quality pharmaceuticals. In an industry where regulatory compliance is closely scrutinized, Venus Remedies' proactive measures position them favorably among global competitors.
About Venus Remedies Limited
Venus Remedies Limited exports 29 products worth $86.4M. Beyond Etoposide, top products include Meropenem, Imipenem, Enoxaparin, Ceftriaxone, Paclitaxel. View the complete Venus Remedies Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Etoposide — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Etoposide shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Venus Remedies Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 144 individual customs records matching Venus Remedies Limited exporting Etoposide, covering 109 formulations to 21 countries via 69 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 122+ countries, 598+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Etoposide Export Data from Venus Remedies Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Venus Remedies Limited's Etoposide exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Venus Remedies Limited
Full Company Profile →
29 products · $86.4M total trade · 6 categories
Etoposide Stats
Company Overview
Top Products by Venus Remedies Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Venus Remedies Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Etoposide. For current shipment-level data, contact TransData Nexus.